Corpus ID: 45533024

Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship.

@article{Carozzi1997PeritonealDE,
  title={Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship.},
  author={S. Carozzi and M. G. Nasini and M. Ravera and A. Sanna and A. Tirotta and S. Lamperi},
  journal={Advances in peritoneal dialysis. Conference on Peritoneal Dialysis},
  year={1997},
  volume={13},
  pages={
          7-12
        }
}
Recent studies have emphasized the role of peritoneal mesothelial cell (PMC) in peritoneal immune defense mechanisms in continuous ambulatory peritoneal dialysis (CAPD). The aim of this study was to evaluate a possible relationship between peritoneal dialysis effluent (PDE), cytokine (Cy) levels, and PMC viability and their impact on peritonitis morbidity. Fifteen patients initiating CAPD for end-stage renal failure participated in the study. The following parameters were evaluated: (1) the… Expand
The Mechanism of Peritoneal Fibrosis in Peritoneal Dialysis
TLDR
High glucose, hypertonicity, low pH, glucose degradation products and advanced glycation end-products in PD solution were suggested to induce TGF-?1 production and play pivotal roles for the progression of PF. Expand
Comparative in vitro Study of Different Peritoneal Dialysis Solutions on Cytokine Production by Peripheral Blood Mononuclear Cells
TLDR
The substitution of pyruvate for lactate buffer seemed to offer an advantage only for the hypertonic glucose-based solutions, while the icodextrin and amino acid solutions seemed close to the isotonic glucose PDS. Expand
Interleukin-6 Levels Decrease in Effluent from Patients Dialyzed with Bicarbonate/Lactate–Based Peritoneal Dialysis Solutions
TLDR
The data suggest that the use of B/L solution is associated with reduced intraperitoneal inflammation and potential for angiogenesis and may, over time, help to restore peritoneal homeostasis and therefore preserve the function of the membrane inPeritoneal dialysis. Expand
Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte‐derived dendritic cells: effect of lactate and glucose‐degradation products
TLDR
PD solutions impaired monocyte‐MDDC differentiation, inhibiting the acquisition of DC markers such as CD1a and DC‐specific intercellular adhesion molecule‐3 grabbing nonintegrin (CD209), which have important implications for the initiation of immune responses under high lactate conditions. Expand
Impact of Fill Volume on Peritoneal Clearances and Cytokine Appearance in Peritoneal Dialysis
TLDR
The results show that, with higher values of DV/BSA ratio, small solute peritoneal clearance is increased, but clearances of large molecules remain unchanged. Expand
Low Immunogenicity Allows Staphylococcus epidermidis to Cause PD Peritonitis
TLDR
Staphylococcus epidermidis strains may be able to cause clinical infection by evoking an inadequate immunological response in the early stage of infection. Expand
Cytokine Responses in Secondary Peritonitis
TLDR
The mechanisms induced by secondary peritonitis related to the production of cytokines are reviewed to determine their role in the onset of local inflammatory responses and in the start of systemic inflammatory responses leading to multiple organ failure. Expand
Nano-sized carriers in gene therapy for peritoneal fibrosis in vivo
TLDR
This review focuses on the use of nano-sized carriers in gene therapy of peritoneal fibrosis in vivo, and various nano- sized carriers, including viral and non-viral vectors, have been shown to enhance the delivery and efficacy of gene therapy for peritoneAL fibrosisIn vivo. Expand
A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness.
TLDR
In CAPD patients with LVH, ARB reduced LVMi in association with alterations in arterial hemodynamics, and this reduction was associated with a reduction in PWV and AI. Expand
Nano-sized carriers in gene therapy for renal fibrosis in vivo
TLDR
This review focuses on the mechanisms of kidneys fibrosis and the in vivo technologies and methodologies of nano-sized carriers in gene therapy for renal fibrosis. Expand